Arrowstreet Capital Limited Partnership Has $154.07 Million Stock Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Arrowstreet Capital Limited Partnership reduced its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 53.1% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 6,990,407 shares of the company’s stock after selling 7,907,218 shares during the period. Arrowstreet Capital Limited Partnership owned about 0.62% of Teva Pharmaceutical Industries worth $154,069,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of TEVA. Wilmington Savings Fund Society FSB acquired a new stake in shares of Teva Pharmaceutical Industries in the third quarter valued at approximately $50,000. Ameliora Wealth Management Ltd. acquired a new stake in Teva Pharmaceutical Industries during the 4th quarter valued at $66,000. IFP Advisors Inc boosted its position in Teva Pharmaceutical Industries by 96.1% during the fourth quarter. IFP Advisors Inc now owns 3,999 shares of the company’s stock worth $88,000 after purchasing an additional 1,960 shares during the period. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new position in shares of Teva Pharmaceutical Industries in the fourth quarter valued at $104,000. Finally, Assetmark Inc. raised its position in shares of Teva Pharmaceutical Industries by 1,370.3% in the fourth quarter. Assetmark Inc. now owns 5,205 shares of the company’s stock valued at $115,000 after purchasing an additional 4,851 shares during the period. Institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

NYSE:TEVA opened at $15.06 on Monday. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. Teva Pharmaceutical Industries Limited has a fifty-two week low of $12.51 and a fifty-two week high of $22.80. The company has a market cap of $17.07 billion, a price-to-earnings ratio of -10.38, a PEG ratio of 1.44 and a beta of 0.82. The stock has a fifty day moving average price of $17.21 and a 200-day moving average price of $18.12.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. As a group, equities analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Piper Sandler lifted their target price on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a report on Friday, January 17th. Bank of America decreased their target price on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating on the stock in a research report on Thursday, March 6th. StockNews.com cut Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a report on Thursday. Barclays decreased their price objective on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a report on Thursday, January 30th. Finally, UBS Group reduced their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research report on Thursday, January 30th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, Teva Pharmaceutical Industries has an average rating of “Moderate Buy” and an average target price of $23.43.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.